4
Changes in Ownership
NewAmsterdam Pharma Co N.V. Filed Acc 0001193125-26-099073
Chief Scientific Officer sold 300,000 shares at an average $30.30 ($9,090,868)
- Chief Scientific Officer acquired 300,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Kastelein Johannes Jacob Pieter · Chief Scientific Officer
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-03-05 | Exercise or conversion : show line 1 in the form 10b5-1 | +104,467 | 173,769 | I | ||
| 2026-03-05 | Sale : show line 2 in the form 10b5-1 | −104,467 | $30.30 | $3,165,350 | 69,302 | I |
| 2026-03-06 | Exercise or conversion : show line 3 in the form 10b5-1 | +94,124 | 163,426 | I | ||
| 2026-03-06 | Sale : show line 4 in the form 10b5-1 | −94,124 | $30.32 | $2,853,840 | 69,302 | I |
| 2026-03-09 | Exercise or conversion : show line 5 in the form 10b5-1 | +101,409 | 170,711 | I | ||
| 2026-03-09 | Sale : show line 6 in the form 10b5-1 | −101,409 | $30.29 | $3,071,679 | 69,302 | I |
| Open-market sales · 300,000 sh · avg $30.30 · $9,090,868 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-03-05 | Exercise or conversion : show line 7 in the form 10b5-1 Option (right to buy) | −104,467 | 715,762 | I |
| 2026-03-06 | Exercise or conversion : show line 8 in the form 10b5-1 Option (right to buy) | −94,124 | 621,638 | I |
| 2026-03-09 | Exercise or conversion : show line 9 in the form 10b5-1 Option (right to buy) | −101,409 | 520,229 | I |
Loading xslF345X05/ownership.xml…